Clinical trials: Fallopian Tube Cancer
Fallopian Tube Cancer, Ovarian Cancer
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: It is not yet known if treatment for recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer is more effective if it is begun when blood levels of CA 125 become elevated rather than waiting for other…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002895
- Testing
- chemotherapy
- Where
- 21 sites in Austria, Belgium and 8 more
- Volunteers
- 1,400 people
- Sponsor
- Medical Research Council
Ovarian Cancer, Fallopian Tube Cancer
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer
Primary Objectives: 1. Determine response rate, time to progression, and toxicity of a schedule of carboplatin by IV (intravenous) infusion, GM-CSF and rIFN-g by SC (subcutaneous injection) in patients with potentially…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00501644
- Testing
- Carboplatin, GM-CSF (Sargramostim), Interferon Gamma
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Anal Cancer, Bladder Cancer
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
RATIONALE: Fiber may lessen bowel side effects caused by radiation therapy. It is not yet known whether a high-fiber diet is more effective than a low-fiber diet in preventing bowel side effects caused by radiation therapy.
- Conditions
- Anal Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer
- Trial name
- NCT01170299
- Testing
- dietary intervention, laboratory biomarker analysis, gastrointestinal complications management/prevention
- Where
- United Kingdom
- Volunteers
- 177 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003385
- Testing
- carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride
- Where
- 8 sites in United States, Norway
- Volunteers
- 48 people
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
RATIONALE: Estrogen may cause the growth of ovarian cancer cells. Hormone therapy using tamoxifen may fight ovarian cancer by blocking the use of estrogen by the tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00305838
- Testing
- tamoxifen citrate, diagnostic laboratory biomarker analysis
- Where
- 24 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Mount Vernon Cancer Centre at Mount Vernon Hospital
Breast Cancer Female, Breast Neoplasm
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
The purpose of this study is to invite all people diagnosed with cancer who meet the eligibility criteria to complete questionnaires before their treatment begins and at regular intervals over time to assess the impact of cancer…
- Conditions
- Breast Cancer Female, Breast Neoplasm, Non-Hodgkin's B-cell Lymphoma, Non-Hodgkin's Lymphoma, Adult High Grade
- Trial name
- NCT03000192
- Where
- 111 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Fallopian Tube Cancer, Ovarian Cancer
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003636
- Testing
- carboplatin, cisplatin, conventional surgery
- Where
- 65 sites in Argentina, Austria and 13 more
- Volunteers
- 704 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Epithelial Ovarian Cancer, Fallopian Tube Neoplasms
SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- SUROVA (NCT06223763)
- Testing
- Cytoreductive surgery, Neoadjuvant chemotherapy, Adjuvant chemotherapy
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Ovarian Cancer
Elizabeth Registry for Low Grade Ovarian Cancer
Long-Term Objectives: To establish an ongoing national research registry of epidemiologic, clinical and pathologic data on low grade and low malignant potential (LMP) ovarian cancer patients in UTMDACC's Department of Gynecologic…
- Trial name
- NCT00345709
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma
A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer
The investigators aimed to evaluate the safety of weekly paclitaxel with oncothermia and weekly cisplatin with oncothermia in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal…
- Conditions
- Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- POPOPO (NCT02344095)
- Testing
- weekly paclitaxel, weekly cisplatin, oncothermia
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Ovarian Cancer, High Grade Serous Carcinoma
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
In BriTROC-2, up to 250 women with a confirmed diagnosis of high-grade serous/high-grade endometrioid or carcinosarcoma will be eligible for full consent (Part 2) and registration to BriTROC-2 and will be followed prospectively…
- Conditions
- Ovarian Cancer, High Grade Serous Carcinoma, Carcinosarcoma, Ovarian, Fallopian Tube Cancer
- Trial name
- BriTROC-2 (NCT05537844)
- Where
- 11 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- Liz-Anne Lewsley
Fallopian Tube Cancer, Ovarian Cancer
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of PEG-interferon alfa-2b and to see how well it works in…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00085384
- Testing
- PEG-interferon alfa-2b
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Primary Objective: 1. Evaluate the efficacy of letrozole to increase the duration of progression-free survival (defined as time to earliest occurrence of local or distant recurrence or clinically significant elevation in CA-125)…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00634894
- Testing
- Femara
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Giving chemotherapy before a peripheral stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00550784
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer
The overall objective of this study is to assess turnaround time, pre-BRCA test onco-genetic counselling quality and satisfaction with a new onco-genetic BRCA testing model.
- Trial name
- ENGAGE (NCT02406235)
- Where
- 26 sites in United States, Italy and 1 more
- Volunteers
- 710 people
- Sponsor
- AstraZeneca
Breast Cancer, Prostate Cancer
Tempus Priority Study: A Pan-tumor Observational Study
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with…
- Conditions
- Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer
- Trial name
- NCT05179824
- Testing
- Observation
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Tempus AI
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or…
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT00499252
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- Where
- 20 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Peritoneal Neoplasms
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
The purposes of this study are: 1. To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) weekly of topotecan in combination with standard dose gefitinib in patients with relapsed, platinum-resistant…
- Conditions
- Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
- Trial name
- NCT00317772
- Testing
- Topotecan, Gefitinib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma, Ovarian Neoplasms
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients for first-line treatment.
- Conditions
- Adenocarcinoma, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00443196
- Testing
- MiCK Assay
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pierian Biosciences
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized phase III trial to compare the effectiveness of tamoxifen with that of thalidomide in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer
- Trial name
- NCT00041080
- Testing
- tamoxifen citrate, thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)